{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Dr. Paika Podcast","title":"Zepbound 10mg to 12.5mg? Watch This Before You Move Up (Doctor Explains)","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/77e930fd\"></iframe>","width":"100%","height":180,"duration":1042,"description":"#Zepbound #Tirzepatide #GLP1 #WeightLossJourney #ObesityMedicine\nThinking about moving from Zepbound 10 mg to 12.5 mg? In this video, I fact-check 4 common claims about the 10 to 12.5 step, using the FDA label and the trial data:\n12.5 mg is a maintenance dose\nIf you’ve stalled on 10, going up will restart your weight loss\nHigher doses mean worse side effects\nYou have to get to 15 mg eventually\nYou’ll learn when it makes sense to stay on 10 and when you might be ready for 12.5. I also cover what the new SURMOUNT-MAINTAIN trial showed, what to do in your first 2 weeks after moving up, and 3 safety notes most people miss.\nI’m Dr. Mohammed Paika, board-certified in Internal Medicine and Obesity Medicine.\n📘 FREE GLP-1 Diet Cookbook (join my newsletter): https://www.drmohammedpaika.com/newsletter\n🎓 GLP-1 Masterclass, now with 4 student tools: https://www.drmohammedpaika.com\n🌐 My new website: https://www.paikahealth.com\n▶️ Watch next, “When Should You Increase or Decrease Your GLP-1 Dose?”: [LINK]\nThis video is for education only and is not medical advice. Talk with your prescriber before changing your dose.\n⏱️ TIMESTAMPS\n0:00 Moving from 10 mg to 12.5 mg\n2:20 Claim 1: 12.5 mg is a maintenance dose\n3:44 Claim 2: Stalled on 10? Going up will restart weight loss\n4:44 How much more does 15 mg actually add?\n6:52 Claim 3: Higher doses mean worse side effects\n8:55 Claim 4: You have to get to 15 mg eventually\n9:37 New data: SURMOUNT-MAINTAIN\n11:00 When to stay on 10 mg\n11:59 When you might be ready for 12.5 mg\n12:49 Your first 2 weeks after moving up\n13:50 3 quick safety notes\n14:52 Scorecard: all 4 claims\n15:44 My take\n16:10 GLP-1 Masterclass\n📚 REFERENCES\nZEPBOUND (tirzepatide) US Prescribing Information. Eli Lilly and Company; revised 8/2026.\nhttps://uspl.lilly.com/zepbound/zepbound.html\nJastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. Funded by Eli Lilly.\nhttps://pubmed.ncbi.nlm.nih.gov/35658024/...","thumbnail_url":"https://img.transistorcdn.com/9qIr9DvwV8ODN3d9cHtpN76KWo0AHFHUFFi87mNWtws/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lNGNl/MTliYWE0MmYyMTY1/NWNjZTA2MWU0Zjgx/N2I5YS5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}